Epicor, a global leader of industry-specific enterprise software to promote business growth, today announced that for the third time in a row it has been positioned as a Leader in the Nucleus Research Configure Price Quote (CPQ) Technology Value Matrix published in November 2024.
Nucleus evaluated Epicor CPQ, a comprehensive solution that simplifies the sales-to-manufacturing process of even the most unique, complex products and offers a visual buying experience across all sales channels. It automates every step in the process from configuring, pricing, and quoting products to generating documentation and controlling machines on the shop floor. Epicor CPQ can be used as a standalone product or integrated with the Epicor Industry ERP Cloud.
“Customers choose Epicor CPQ for an end-to-end solution that will drive customer engagement and help boost revenues,” said Vaibhav Vohra, President of Epicor. “Epicor's continued positioning as a Leader in the Nucleus CPQ Technology Value Matrix is a testament to the power and value it delivers for our customers.”
In the ranking report, Nucleus highlighted “significant enhancements to its 3D visualization tools, including improvements to patent-pending Sketch & Extrude for greater design flexibility and Apple Vision Pro integration for spatial computing and augmented reality experiences.” They also applauded expanded functionality for administrators to “easily manage configurators, such as copying UI modules between them and applying single rules to multiple configurators for mass updates.”
For more information on Epicor CPQ, please visit our website.
About Nucleus Research
Nucleus Research is a global provider of investigative, case-based technology research and advisory services. The company’s ROI-focused research approach provides unique insight into the actual results technology solutions deliver, allowing organizations to cut through marketing hype to understand real operational value and select or renew the best technology solution for their environment. For more information, visit NucleusResearch.com, or follow the latest updates on LinkedIn.
